RE: RIP Friday FOMO?27 Nov 2020 18:11
It seems the Market is becoming a little jaundiced by Avacta, with so much promise but little yet delivered, and the flurry of RNS ‘good news’ releases prior to its sudden £40m Share Placing, hasn’t helped investor confidence. Whilst a positive BAMS update will be welcomed I don’t now expect this in itself to be a SP catalyst. Markets look ahead and it seems more of an accepted result, but if not delivered we will pay a price.
Firm diagnostic contracts and revenue projections are really the only drivers that will now see this SP move in the right direction, otherwise it will be for the therapeutics division to deliver. We held up well this week.